Theriva Biologics Files 8-K
Ticker: TOVX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2,894,225 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Company Update
TL;DR
Theriva Biologics filed an 8-K on Oct 29, 2025, with SEC.
AI Summary
Theriva Biologics, Inc. filed an 8-K on October 29, 2025, reporting other events and financial statements. The company, formerly known as Synthetic Biologics, Inc., is incorporated in Nevada and headquartered in Rockville, Maryland.
Why It Matters
This filing indicates Theriva Biologics is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing with no immediate financial or operational impact disclosed.
Key Numbers
- 001-12584 — Commission File Number (SEC filing identifier)
- 13-3808303 — IRS Employer Identification No. (Company tax identifier)
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- October 29, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Rockville, Maryland (location) — Business address
FAQ
What specific 'Other Events' are being reported by Theriva Biologics in this 8-K?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
When was Theriva Biologics previously known as Synthetic Biologics, Inc.?
The filing states the former company name was Synthetic Biologics, Inc., with a date of name change of 20120305.
What is the primary business classification for Theriva Biologics?
Theriva Biologics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
Where is Theriva Biologics, Inc. headquartered?
The company's business address is listed as 9605 Medical Center Drive, Suite 270, Rockville, Maryland.
What is the fiscal year end for Theriva Biologics?
The fiscal year end for Theriva Biologics, Inc. is December 31 (1231).
Filing Stats: 853 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-10-29 16:57:33
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
- $2,894,225 — relating to the offer and sale of up to $2,894,225 of shares of the Company's common stock
Filing Documents
- tm2529686d1_8k.htm (8-K) — 30KB
- tm2529686d1_ex5-1.htm (EX-5.1) — 10KB
- tm2529686d1_ex5-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-25-103774.txt ( ) — 219KB
- syn-20251029.xsd (EX-101.SCH) — 3KB
- syn-20251029_lab.xml (EX-101.LAB) — 33KB
- syn-20251029_pre.xml (EX-101.PRE) — 22KB
- tm2529686d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On October 29, 2025, Theriva Biologics, Inc. (the "Company") filed a prospectus supplement and the accompanying base prospectus (the "Prospectus Supplement") to its Registration Statement on Form S-3, as amended (File No. 333-279077), which Form S-3 was declared effective by the Securities and Exchange Commission (the "Commission") on September 25, 2024 (the "Registration Statement"), relating to the offer and sale of up to $2,894,225 of shares of the Company's common stock, par value $0.001 per share (the "common stock"), from time to time through or directly to A.G.P./Alliance Global Partners (the "Sales Agent") pursuant to the terms of that certain Amended and Restated At Market Issuance Sales Agreement, dated February 9, 2021, as amended by Amendment No. 1 thereto, dated May 3, 2021, as further amended by Amendment No. 2 thereto, dated May 2, 2024 (the "Sales Agreement"). Sales of the common stock, if any, under the Prospectus Supplement will be made by any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The Sales Agent is not required to sell any specific amount, but will act as our Sales Agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The Sales Agent will be entitled to compensation at a commission rate equal to up to 3.0% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, the Sales Agent will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities under the Se
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit Number Description 5.1 Opinion of Parsons Behle & Latimer 23.1 Consent of Parsons Behle & Latimer (included in Exhibit 5.1 hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 29, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer